Back to Journals » Diabetes, Metabolic Syndrome and Obesity » Volume 11

Statin on insulin and adiponectin levels: true or false prophecy?

Authors Jonnalagadda VG , Shaik A

Received 26 December 2017

Accepted for publication 28 December 2017

Published 12 April 2018 Volume 2018:11 Pages 131—132

DOI https://doi.org/10.2147/DMSO.S160853

Checked for plagiarism Yes

Editor who approved publication: Professor Ming-Hui Zou



Venu Gopal Jonnalagadda,1 Afsar Shaik2

1Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research, Bhangagarh, Guwahati, Assam, India; 2Department of Pharmacology, Narayana Pharmacy College, Chinthareddy Palem, Nellore, Andhra Pradesh, India

We read the article “Effect of different doses of statins on the development of type 2 diabetes mellitus in patients with myocardial infarction” by Gruzdeva et al1 with interest. The authors conducted a prospective cohort study on patients with diagnosed myocardial infarction who were on different doses of atorvastatin, ie, 20 mg/d or 40 mg/d, for new onset of diabetes for a duration of 12 months.

Authors’ reply

Evgenya Uchasova, Olga Gruzdeva

Federal State Budgetary Institution, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation


We would like to thank Venu Gopal Jonnalagadda and Afsar Shaik for the letter in response to our article.1 Yes, indeed in our study, statins at a dose of 20 and 40 mg/mL, at 20 mg/d atorvastatin, were observed to improve the sensitivity to insulin and eliminate adipokine imbalance and ghrelin deficiency. At a dose of 40 mg/d, atorvastatin showed increased negative effects, such as a reduction in insulin secretion, hyperglycemia, impaired glucose tolerance, high levels of leptin, ghrelin deficiency, and manifestation of type 2 diabetes mellitus. Statins at a dose of 80 mg/mL were not included in this work; however, at this dose in this study, we observed a decrease in levels of adiponectin and insulin.1

View the original paper by Gruzdeva and colleagues.

Dear editor

We read the article “Effect of different doses of statins on the development of type 2 diabetes mellitus in patients with myocardial infarction” by Gruzdeva et al1 with interest. The authors conducted a prospective cohort study on patients with diagnosed myocardial infarction who were on different doses of atorvastatin, ie, 20 mg/d or 40 mg/d, for new onset of diabetes for a duration of 12 months.

In the results, the authors presented that (Table 2) the levels of insulin in group 1 (atorvastatin 20 mg/d) were 12.95 mU/mL (8.50; 14.60) on day 1 and 9.96 mU/mL (7.40; 12.70) at 1 year. In same vein, the levels of insulin in group 2 (atorvastatin 40 mg/d) were 12.5 mU/mL (8.90; 15.92) on day 1 and 12.67 mU/mL (9.74; 15.70) at 1 year. Moreover, the levels of adipokines (Table 3), ie, adiponectin, in group 1 (atorvastatin 20 mg/d) were 9.1 mg/mL (7.10; 12.40) on day 1 and 14.4 mg/mL (10.70; 17.00) at 1 year. In the case of group 2, the levels (atorvastatin 40 mg/d) were 8.7 mg/mL (5.50; 12.80) on day 1 and 10.6 mg/mL (7.40; 12.80) at 1 year.1

After careful consideration, it can be understood that increased dose of statin did not affect insulin and adiponectin levels in a dose-dependent manner. In contrast to this, there were eight cases (20.5%) in the atorvastatin 40 mg/d group and one case (2.6%) in the atorvastatin 20 mg/d group diagnosed with new onset of diabetes out of 39 patients in each group.1

In general, and accumulating data reiterates that, statins cause dose-dependent decrease in the levels of adiponectin and insulin and increase in the levels of glucose, ie, hyperglycemia. On the contrary, the authors presented that the levels of glucose increased along with insulin and adiponectin levels rather than decreased.24

We would be much obliged if you would kindly clarify these issues, and we also believe that managing cardiovascular events is important with statins after assessing the risk versus benefit ratio.

Disclosure

The authors report no conflicts of interest in this communication.

References

1.

Gruzdeva O, Uchasova E, Dyleva Y, et al. Effect of different doses of statins on the development of type 2 diabetes mellitus in patients with myocardial infarction. Diabetes Metab Syndr Obes. 2017;10:481–489.

2.

Sattar N, Taskinen MR. Statins are diabetogenic – myth or reality? Atheroscler Suppl. 2012;13:1–10.

3.

Jonnalagadda VG, Choudhary K, Matety VK. Statins and new onset of diabetes: which one outweighs risk or benefit? Postgrad Med. 2018:130(1):146.

4.

Maki KC, Diwadkar-Navsariwala V, Kramer MW. Statin use and risk for type 2 diabetes: what clinicians should know. Postgrad Med. 2017;22:1–7.

Authors’ reply

Evgenya Uchasova, Olga Gruzdeva

Federal State Budgetary Institution, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation

Correspondence: Evgenya Uchasova, Federal State Budgetary Institution, Research Institute for Complex Issues of Cardiovascular Disease, Laboratory of Research Homeostasis, 6 Sosnovy Boulevard, Kemerovo 650002, Russian Federation
Tel +7 384 2640 553
Fax +7 384 2643 410
Email [email protected]

Dear editor

We would like to thank Venu Gopal Jonnalagadda and Afsar Shaik for the letter in response to our article.1 Yes, indeed in our study, statins at a dose of 20 and 40 mg/mL, at 20 mg/d atorvastatin, were observed to improve the sensitivity to insulin and eliminate adipokine imbalance and ghrelin deficiency. At a dose of 40 mg/d, atorvastatin showed increased negative effects, such as a reduction in insulin secretion, hyperglycemia, impaired glucose tolerance, high levels of leptin, ghrelin deficiency, and manifestation of type 2 diabetes mellitus. Statins at a dose of 80 mg/mL were not included in this work; however, at this dose in this study, we observed a decrease in levels of adiponectin and insulin.1

Disclosure

The authors report no conflicts of interest in this communication.

Reference

1.

Gruzdeva O, Uchasova E, Dyleva Y, et al. Effect of different doses of statins on the development of type 2 diabetes mellitus in patients with myocardial infarction. Diabetes Metab Syndr Obes. 2017;10:481–489.

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy ‘letters to the editor’ section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Creative Commons License © 2018 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.